ArticleJournal, genetic engineering & biotechnology2025
Exploration of Canarium odontophyllum fruit phytoconstituents as potential candidates against epilepsy using in silico studies.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is the third most common neurological illness worldwide, affecting over 65 million people. Current antiepileptic drugs (AEDs) are ineffective for about 30 % of epileptic patients. AED use is extremely expensive and associated with adverse effects such as ataxia, nystagmus, and central nervous system depression. Serious quality-of-life changes are another aspect of managing epileptic conditions. A variety of therapeutic plant components, including flavonoids, phenolics, terpenoids, and alkaloids, exhibit a wide range of biological actions, including antibacterial, antioxidant, antiulcer, antineoplastic, anti-inflammatory, antiepileptic, and immunostimulant properties. Because many of them are being researched in modern research to develop an active therapeutic candidate, we resorted to medicinal plants to investigate powerful antiepileptic components. So, in this in silico study, we aimed to identify potential antiepileptic agents from Canarium odontophyllum fruits using molecular docking, molecular dynamics, and ADMET prediction approach. In the present study, the virtual screening was performed on a set of 63 phytocompounds, identified from the hydroalcoholic (70 %) extract of C. odontophyllum fruit using LC-MS (LC-MS-QTOF) analysis, by using molecular docking simulation to examine their binding ability with seven proteins that are responsible for epilepsy. Further, the selected compounds with good binding affinity were subjected to ADMET screening to predict the pharmacokinetic properties, and molecular dynamics testing was done to confirm the outcomes. Our results revealed that C. odontophyllum phytoconstituents showed the strongest binding affinities against all tested enzymes. Moreover, kanzonol B could prominently interact with all tested proteins with moderate to good binding affinity (-6.70 to -10.65 kcal/mol). All top phytoconstituents obeyed Lipinski's RO5 and drug-likeness properties. These computational studies suggested that the phytoconstituents of C. odontophyllum can serve as potent inhibitors of enzymes responsible for epilepsy. Thus, we recommend further experimental investigations to validate the promising results of the present in silico study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.